PerkinElmer and Waters Announce Collaboration for Advanced Neonatal Screening Solutions
PerkinElmer Inc. (NYSE: PKI), the world’s leading provider of neonatal screening systems and Waters Corporation (NYSE: WAT), a premier supplier of mass spectrometers have entered into a long-term collaboration with a reagent/software/mass spectrometry/liquid chromatography platform to deliver advanced newborn screening solutions.
Through this agreement, PerkinElmer will become the exclusive distributor of the Waters(R) Quattro micro(TM) and Waters Quattro Premier (TM) MS/MS platforms and the Alliance(R) HPLC System for neonatal screening applications. Newborn screening for metabolic disorders has become one of the most widely accepted procedures in preventative pediatrics. In August 2004, PerkinElmer became the only company in the world to receive clearance from the U.S. Food and Drug Administration for its Neogram(R) Tandem Mass Spectrometry Kit (TMS). PerkinElmer’s TMS system is helping to drive the global standardization of metabolic screening with the capability to analyze more than 40 disease markers with a single blood sample. Early detection increases treatment and management options, leading to an improved quality of life. PerkinElmer provides a complete screening solution from sample collection to results reporting.
“We are pleased to collaborate with Waters on their mass spectrometry technologies in our integrated solutions for newborn screening,” said Peter B. Coggins, Ph.D., president of PerkinElmer Life & Analytical Sciences. “Through this agreement, our mutual goal is to ensure a pipeline of advanced and integrated products that protect the health of newborns. We are excited about our growth prospects in this area, and remain committed to supporting all existing customer equipment configurations.”
“We are excited to deliver our market leading mass spectrometry technologies into the high-growth neonatal screening markets. This partnership with PerkinElmer will help speed the development and release of products to enable early intervention and treatment thereby improving the health of newborns, lower healthcare costs and save lives,” said Michael Yelle, Senior Director – Clinical Business Operations at Waters Corporation. “PerkinElmer has broad knowledge and experience in the field of newborn screening, especially in the development and manufacture of reagents and application software, while Waters provides market-leading, high-quality tandem mass spectrometers.”
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Industrial Sciences markets to improve the quality of life. The Company reported revenues of $1.7 billion in 2004, has 10,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Waters Corporation holds worldwide leading positions in three complementary analytical technologies – liquid chromatography, mass spectrometry and thermal analysis. These markets account for $4.5 – $5.0 billion of the overall $20 + billion analytical instrument market.
Waters, Alliance, Quattro micro, and Quattro Premier are trademarks of Waters Corporation.
